SG Americas Securities LLC increased its stake in Anika Therapeutics, Inc. (NASDAQ:ANIK – Free Report) by 43.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,485 shares of the biotechnology company’s stock after purchasing an additional 2,858 shares during the period. SG Americas Securities LLC owned 0.07% of Anika Therapeutics worth $234,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Lazard Asset Management LLC bought a new position in Anika Therapeutics in the 1st quarter worth approximately $180,000. State Board of Administration of Florida Retirement System bought a new position in Anika Therapeutics in the 1st quarter worth approximately $198,000. BNP Paribas Financial Markets raised its position in Anika Therapeutics by 16.9% in the 1st quarter. BNP Paribas Financial Markets now owns 22,240 shares of the biotechnology company’s stock worth $565,000 after purchasing an additional 3,217 shares during the last quarter. American Century Companies Inc. raised its position in Anika Therapeutics by 11.8% in the 2nd quarter. American Century Companies Inc. now owns 23,892 shares of the biotechnology company’s stock worth $605,000 after purchasing an additional 2,518 shares during the last quarter. Finally, Ironwood Investment Management LLC raised its position in Anika Therapeutics by 109.9% in the 2nd quarter. Ironwood Investment Management LLC now owns 28,704 shares of the biotechnology company’s stock worth $727,000 after purchasing an additional 15,032 shares during the last quarter. Institutional investors own 91.53% of the company’s stock.
Anika Therapeutics Stock Performance
ANIK opened at $24.44 on Tuesday. The company has a fifty day moving average price of $25.11 and a two-hundred day moving average price of $25.81. Anika Therapeutics, Inc. has a 52 week low of $18.08 and a 52 week high of $29.11. The firm has a market capitalization of $356.51 million, a PE ratio of -4.66 and a beta of 0.83.
Wall Street Analysts Forecast Growth
Separately, Barrington Research restated an “outperform” rating and issued a $37.00 price objective on shares of Anika Therapeutics in a research report on Friday, August 9th.
Read Our Latest Stock Report on Anika Therapeutics
Anika Therapeutics Company Profile
Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.
Further Reading
- Five stocks we like better than Anika Therapeutics
- 3 Small Caps With Big Return Potential
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- What is Put Option Volume?
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- What is a Special Dividend?
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.